Category: Sleep Disorders

Sleep Disorders

FDA Grants Fast Track Designation to Investigational Narcolepsy Treatment

The oral orexin 2 receptor agonist currently in phase 1b development for patients with narcolepsy.

Sleep Disorders

Why Microsleeps May Redefine ‘Quality of Wake’ in Narcolepsy Type 1

Phase 3 data on the orexin agonist oveporexton suggests that reducing microsleep frequency offers a more accurate reflection of real-world treatment response than traditional wakefulness tests alone.

Sleep Disorders

Surprising Duration of Self-Maintained Positional Therapy Benefits Offers New OSA Strategy

Research presented at ATS 2026 reveals that positional therapy conditions patients to avoid back-sleeping, maintaining obstructive sleep apnea control for up to a year after device withdrawal.

Breathing Disorders

Lilly’s Investigational Triple Agonist Retatrutide Reduces OSA Severity in Phase 3 Trial

Phase 3 TRIUMPH-1 trial data show retatrutide reduced the AHI by up to 36.1 events per hour alongside substantial weight loss.

Insomnia

Drug Used Off-Label for Insomnia Improves Sleep But Impairs Next-Day Alertness in OSA Patients

Flinders University researchers have led a clinical trial examining how a commonly prescribed ‘sleeping pill’ affects sleep, breathing, and next‑day performance.

Hypersomnias

Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments

Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, securing a portfolio of clinical-stage orexin receptor 2 agonists. This strategic move aims to accelerate the development of new treatments for narcolepsy and other sleep-wake disorders.

Movement Disorders

Resmed Acquires Noctrix Health to Enter Restless Legs Syndrome Market

The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.

Circadian Rhythm Disorders

Drug Shows Promise for Reducing Excessive Sleepiness in Early Morning Shift Workers

A new clinical trial from Mass General Brigham found that a drug approved for other indications helped early morning shift workers with shift work disorder stay more alert.

Parasomnias

Teen Scholar Recognized for Research on Sleep Paralysis in Adolescents

Yanchen Wang is named among 300 scholars in the Regeneron Science Talent Search 2026 for her project investigating the characteristics and risk factors of the parasomnia.